Details of the Drug

General Information of Drug (ID: DML8KTN)

Drug Name
Danazol
Synonyms
Anatrol; Chronogyn; Cyclomen; Danatrol; Danazant; Danazole; Danazolum; Danocrine; Danogen; Danokrin; Danol; Danoval; Danzol; Ladogal; Norciden; Panacrine; Winobanin; Alphapharm Brand of Danazol; Antigen Brand of Danazol; Kendrick Brand of Danazol; Ratiopharm Brand of Danazol; Sanofi Brand of Danazol; Sanofi Synthelabo Brand ofDanazol; Sanofi Winthrop Brand of Danazol; WIN 17757; Danazol-ratiopharm; Danazolum [INN-Latin]; Danocrine (TN); WIN 17,757; WIN-17757; Win 17, 757; Danazol (JAN/USP/INN); Danazol [USAN:BAN:INN:JAN];[1,2]oxazolo[4',5':2,3]-17alpha-pregn-4-en-20-yn-17-ol; (1R,3aS,3bR,10aR,10bS,12aS)-1-ethynyl-10a,12a-dimethyl-2,3,3a,3b,4,5,10,10a,10b,11,12,12a-dodecahydro-1H-cyclopenta[7,8]phenanthro[3,2-d]isoxazol-1-ol; (1S,2R,13R,14S,17R,18S)-17-ethynyl-2,18-dimethyl-7-oxa-6-azapentacyclo[11.7.0.0^{2,10}.0^{4,8}.0^{14,18}]icosa-4(8),5,9-trien-17-ol; 1-Ethynyl-10a,12a-dimethyl-2,3,3a,3b,4,5,10,10a,10b,11,12,12a-dodecahydro-1H-cyclopenta[7,8]phenanthro[3,2-d]isoxazol-1-ol; 17-alpha-2,4-Pregnadien-20-yno(2,3-d)isoxazol-17-ol; 17-alpha-Pregn-4-en-20-yno(2,3-d)isoxazol-17-ol; 17-alpha-Pregna-2,4-dien-20-yno(2,3-d)isoxazol-17-ol; 17.Alpha.-Pregna-2, {4-dien-20-yno[2,3-d]isoxazol-17-ol}; 17alpha-Pregna-2,4-dien-20-yno(2,3-d)isoxazol-17-ol
Indication
Disease Entry ICD 11 Status REF
Menorrhagia GA20.50 Approved [1]
Breast cancer 2C60-2C65 Phase 2 [1]
Breast fibrocystic disease N.A. Investigative [2]
Endometriosis GA10 Investigative [2]
Therapeutic Class
Fertility Agents
Affected Organisms
Humans and other mammals
ATC Code
G03XA01: Danazol
G03XA: Antigonadotropins and similar agents
G03X: OTHER SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM
G03: SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM
G: GENITO URINARY SYSTEM AND SEX HORMONES
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 337.5
Logarithm of the Partition Coefficient (xlogp) 3.8
Rotatable Bond Count (rotbonds) 1
Hydrogen Bond Donor Count (hbonddonor) 1
Hydrogen Bond Acceptor Count (hbondacc) 3
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [3]
Clearance
The drug present in the plasma can be removed from the body at the rate of 15.71 mL/min/kg [4]
Half-life
The concentration or amount of drug in body reduced by one-half in 24 hours [4]
Metabolism
The drug is metabolized via the hepatic []
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 33.78225 micromolar/kg/day [5]
Vd
Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 5.18 L/kg [4]
Water Solubility
The ability of drug to dissolve in water is measured as 0.0009 mg/mL [3]
Chemical Identifiers
Formula
C22H27NO2
IUPAC Name
(1S,2R,13R,14S,17R,18S)-17-ethynyl-2,18-dimethyl-7-oxa-6-azapentacyclo[11.7.0.02,10.04,8.014,18]icosa-4(8),5,9-trien-17-ol
Canonical SMILES
C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=CC5=C(C[C@]34C)C=NO5
InChI
InChI=1S/C22H27NO2/c1-4-22(24)10-8-18-16-6-5-15-11-19-14(13-23-25-19)12-20(15,2)17(16)7-9-21(18,22)3/h1,11,13,16-18,24H,5-10,12H2,2-3H3/t16-,17+,18+,20+,21+,22+/m1/s1
InChIKey
POZRVZJJTULAOH-LHZXLZLDSA-N
Cross-matching ID
PubChem CID
28417
ChEBI ID
CHEMBL1479
CAS Number
17230-88-5
UNII
N29QWW3BUO
DrugBank ID
DB01406
TTD ID
D09IPV
INTEDE ID
DR2401
ACDINA ID
D00165
Drug-Molecule Activity Atlas (DMA)NEW Click to Jump to the Detailed DMA Information of This Drug
Drug Pharmacogenomic Perturbation (DPP)NEW Click to Jump to the Detailed DPP Information of This Drug
Drug ADMET Endpoint Profile (DAE)NEW Click to Jump to the Detailed DAE Information of This Drug
Combinatorial Drugs (CBD) Click to Jump to the Detailed CBD Information of This Drug
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Estrogen receptor (ESR) TTZAYWL ESR1_HUMAN Antagonist [6]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Bile salt export pump (ABCB11) OTRU7THO ABCBB_HUMAN Gene/Protein Processing [7]
Cyclin-dependent kinase inhibitor 1 (CDKN1A) OTQWHCZE CDN1A_HUMAN Gene/Protein Processing [8]
Plasma protease C1 inhibitor (SERPING1) OT6CVN45 IC1_HUMAN Gene/Protein Processing [9]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Menorrhagia
ICD Disease Classification GA20.50
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Estrogen receptor (ESR) DTT ESR1 2.05E-08 -0.08 -0.31
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Danazol (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Remdesivir DMBFZ6L Moderate Increased risk of hepatotoxicity by the combination of Danazol and Remdesivir. 1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019] [10]
Midostaurin DMI6E0R Moderate Decreased metabolism of Danazol caused by Midostaurin mediated inhibition of CYP450 enzyme. Acute myeloid leukaemia [2A60] [11]
Gilteritinib DMTI0ZO Moderate Decreased metabolism of Danazol caused by Gilteritinib mediated inhibition of CYP450 enzyme. Acute myeloid leukaemia [2A60] [12]
Ivabradine DM0L594 Moderate Decreased metabolism of Danazol caused by Ivabradine mediated inhibition of CYP450 enzyme. Angina pectoris [BA40] [12]
Dronedarone DMA8FS5 Moderate Decreased metabolism of Danazol caused by Dronedarone mediated inhibition of CYP450 enzyme. Angina pectoris [BA40] [13]
Bedaquiline DM3906J Moderate Increased risk of hepatotoxicity by the combination of Danazol and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [14]
Cariprazine DMJYDVK Moderate Decreased metabolism of Danazol caused by Cariprazine mediated inhibition of CYP450 enzyme. Bipolar disorder [6A60] [12]
Pexidartinib DMS2J0Z Major Increased risk of hepatotoxicity by the combination of Danazol and Pexidartinib. Bone/articular cartilage neoplasm [2F7B] [15]
Ixabepilone DM2OZ3G Moderate Decreased metabolism of Danazol caused by Ixabepilone mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [16]
Palbociclib DMD7L94 Moderate Decreased metabolism of Danazol caused by Palbociclib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [12]
Bosutinib DMTI8YE Moderate Decreased metabolism of Danazol caused by Bosutinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [12]
Macitentan DMP79A1 Moderate Decreased metabolism of Danazol caused by Macitentan mediated inhibition of CYP450 enzyme. Cardiovascular disease [BA00-BE2Z] [17]
PF-04449913 DMSB068 Moderate Decreased metabolism of Danazol caused by PF-04449913 mediated inhibition of CYP450 enzyme. Chronic myelomonocytic leukaemia [2A40] [18]
Indacaterol DMQJHR7 Minor Decreased metabolism of Danazol caused by Indacaterol mediated inhibition of CYP450 enzyme. Chronic obstructive pulmonary disease [CA22] [19]
Ulipristal DMBNI20 Minor Decreased metabolism of Danazol caused by Ulipristal mediated inhibition of CYP450 enzyme. Contraceptive management [QA21] [12]
Osilodrostat DMIJC9X Moderate Decreased metabolism of Danazol caused by Osilodrostat mediated inhibition of CYP450 enzyme. Cushing syndrome [5A70] [12]
Ivacaftor DMZC1HS Moderate Decreased metabolism of Danazol caused by Ivacaftor mediated inhibition of CYP450 enzyme. Cystic fibrosis [CA25] [20]
Vilazodone DM4LECQ Moderate Decreased metabolism of Danazol caused by Vilazodone mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [21]
Polatuzumab vedotin DMF6Y0L Moderate Decreased metabolism of Danazol caused by Polatuzumab vedotin mediated inhibition of CYP450 enzyme. Diffuse large B-cell lymphoma [2A81] [22]
Stiripentol DMMSDOY Moderate Decreased metabolism of Danazol caused by Stiripentol mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [12]
Cannabidiol DM0659E Moderate Increased risk of hepatotoxicity by the combination of Danazol and Cannabidiol. Epileptic encephalopathy [8A62] [12]
Tazemetostat DMWP1BH Moderate Decreased metabolism of Danazol caused by Tazemetostat mediated inhibition of CYP450 enzyme. Follicular lymphoma [2A80] [23]
Mirabegron DMS1GYT Minor Decreased metabolism of Danazol caused by Mirabegron mediated inhibition of CYP450 enzyme. Functional bladder disorder [GC50] [24]
Ripretinib DM958QB Moderate Decreased metabolism of Danazol caused by Ripretinib mediated inhibition of CYP450 enzyme. Gastrointestinal stromal tumour [2B5B] [10]
Avapritinib DMK2GZX Moderate Decreased metabolism of Danazol caused by Avapritinib mediated inhibition of CYP450 enzyme. Gastrointestinal stromal tumour [2B5B] [12]
Brentuximab vedotin DMWLC57 Moderate Increased risk of hepatotoxicity by the combination of Danazol and Brentuximab vedotin. Hodgkin lymphoma [2B30] [25]
MK-1439 DM215WE Minor Decreased metabolism of Danazol caused by MK-1439 mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [26]
Dolutegravir DMCZGRE Minor Decreased metabolism of Danazol caused by Dolutegravir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [27]
Etravirine DMGV8QU Moderate Decreased metabolism of Danazol caused by Etravirine mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [28]
Lopinavir DMITQS0 Minor Decreased metabolism of Danazol caused by Lopinavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [12]
Rilpivirine DMJ0QOW Moderate Decreased metabolism of Danazol caused by Rilpivirine mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [10]
Maraviroc DMTL94F Moderate Decreased metabolism of Danazol caused by Maraviroc mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [29]
Mipomersen DMGSRN1 Major Increased risk of hepatotoxicity by the combination of Danazol and Mipomersen. Hyper-lipoproteinaemia [5C80] [30]
Teriflunomide DMQ2FKJ Major Increased risk of hepatotoxicity by the combination of Danazol and Teriflunomide. Hyper-lipoproteinaemia [5C80] [31]
BMS-201038 DMQTAGO Major Increased risk of hepatotoxicity by the combination of Danazol and BMS-201038. Hyper-lipoproteinaemia [5C80] [32]
Suvorexant DM0E6S3 Moderate Decreased metabolism of Danazol caused by Suvorexant mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [10]
ITI-007 DMUQ1DO Moderate Decreased metabolism of Danazol caused by ITI-007 mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [33]
Naloxegol DML0B41 Major Decreased metabolism of Danazol caused by Naloxegol mediated inhibition of CYP450 enzyme. Large intestine motility disorder [DB32] [12]
Pemigatinib DM819JF Moderate Decreased metabolism of Danazol caused by Pemigatinib mediated inhibition of CYP450 enzyme. Liver cancer [2C12] [12]
Crizotinib DM4F29C Moderate Decreased metabolism of Danazol caused by Crizotinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [34]
Brigatinib DM7W94S Moderate Decreased metabolism of Danazol caused by Brigatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [10]
Ceritinib DMB920Z Moderate Decreased metabolism of Danazol caused by Ceritinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [35]
Lurbinectedin DMEFRTZ Moderate Decreased metabolism of Danazol caused by Lurbinectedin mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [36]
PF-06463922 DMKM7EW Moderate Decreased metabolism of Danazol caused by PF-06463922 mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [37]
Osimertinib DMRJLAT Moderate Decreased metabolism of Danazol caused by Osimertinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [38]
Pralsetinib DMWU0I2 Moderate Decreased metabolism of Danazol caused by Pralsetinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [39]
Selpercatinib DMZR15V Moderate Decreased metabolism of Danazol caused by Selpercatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [12]
Calaspargase pegol DMQZBXI Moderate Increased risk of hepatotoxicity by the combination of Danazol and Calaspargase pegol. Malignant haematopoietic neoplasm [2B33] [40]
Idelalisib DM602WT Moderate Increased risk of hepatotoxicity by the combination of Danazol and Idelalisib. Mature B-cell leukaemia [2A82] [41]
GDC-0199 DMH0QKA Moderate Decreased metabolism of Danazol caused by GDC-0199 mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [10]
IPI-145 DMWA24P Moderate Decreased metabolism of Danazol caused by IPI-145 mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [42]
Acalabrutinib DM7GCVW Moderate Decreased metabolism of Danazol caused by Acalabrutinib mediated inhibition of CYP450 enzyme. Mature B-cell lymphoma [2A85] [43]
Ibrutinib DMHZCPO Moderate Decreased metabolism of Danazol caused by Ibrutinib mediated inhibition of CYP450 enzyme. Mature B-cell lymphoma [2A85] [44]
Selumetinib DMC7W6R Moderate Decreased metabolism of Danazol caused by Selumetinib mediated inhibition of CYP450 enzyme. Melanoma [2C30] [45]
Ubrogepant DM749I3 Moderate Decreased metabolism of Danazol caused by Ubrogepant mediated inhibition of CYP450 enzyme. Migraine [8A80] [46]
Flibanserin DM70DTN Moderate Decreased metabolism of Danazol caused by Flibanserin mediated inhibition of CYP450 enzyme. Mood disorder [6A60-6E23] [47]
Carfilzomib DM48K0X Major Additive thrombogenic effects by the combination of Danazol and Carfilzomib. Multiple myeloma [2A83] [10]
Panobinostat DM58WKG Moderate Decreased metabolism of Danazol caused by Panobinostat mediated inhibition of CYP450 enzyme. Multiple myeloma [2A83] [48]
Nilotinib DM7HXWT Moderate Decreased metabolism of Danazol caused by Nilotinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [49]
Ruxolitinib DM7Q98D Minor Decreased metabolism of Danazol caused by Ruxolitinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [12]
Entrectinib DMMPTLH Moderate Decreased metabolism of Danazol caused by Entrectinib mediated inhibition of CYP450 enzyme. Non-small cell lung cancer [2C25] [50]
Olaparib DM8QB1D Moderate Decreased metabolism of Danazol caused by Olaparib mediated inhibition of CYP450 enzyme. Ovarian cancer [2C73] [51]
Pimavanserin DMR7IVC Moderate Decreased metabolism of Danazol caused by Pimavanserin mediated inhibition of CYP450 enzyme. Parkinsonism [8A00] [52]
Lefamulin DME6G97 Moderate Decreased metabolism of Danazol caused by Lefamulin mediated inhibition of CYP450 enzyme. Pneumonia [CA40] [53]
Lonafarnib DMGM2Z6 Major Decreased metabolism of Danazol caused by Lonafarnib mediated inhibition of CYP450 enzyme. Premature ageing appearance [LD2B] [54]
Enzalutamide DMGL19D Moderate Decreased metabolism of Danazol caused by Enzalutamide mediated inhibition of CYP450 enzyme. Prostate cancer [2C82] [55]
Silodosin DMJSBT6 Moderate Decreased metabolism of Danazol caused by Silodosin mediated inhibition of CYP450 enzyme. Prostate hyperplasia [GA90] [56]
Everolimus DM8X2EH Moderate Decreased metabolism of Danazol caused by Everolimus mediated inhibition of CYP450 enzyme. Renal cell carcinoma [2C90] [57]
Axitinib DMGVH6N Moderate Decreased metabolism of Danazol caused by Axitinib mediated inhibition of CYP450 enzyme. Renal cell carcinoma [2C90] [12]
Temsirolimus DMS104F Moderate Decreased metabolism of Danazol caused by Temsirolimus mediated inhibition of CYP450 enzyme. Renal cell carcinoma [2C90] [58]
LDE225 DMM9F25 Moderate Decreased metabolism of Danazol caused by LDE225 mediated inhibition of CYP450 enzyme. Skin cancer [2C30-2C37] [59]
Larotrectinib DM26CQR Moderate Decreased metabolism of Danazol caused by Larotrectinib mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [10]
Trabectedin DMG3Y89 Moderate Increased risk of hepatotoxicity by the combination of Danazol and Trabectedin. Solid tumour/cancer [2A00-2F9Z] [12]
Armodafinil DMGB035 Minor Decreased metabolism of Danazol caused by Armodafinil mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [10]
LEE011 DMMX75K Moderate Decreased metabolism of Danazol caused by LEE011 mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [10]
Elagolix DMB2C0E Moderate Decreased metabolism of Danazol caused by Elagolix mediated inhibition of CYP450 enzyme. Uterine fibroid [2E86] [60]
⏷ Show the Full List of 76 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Allura red AC dye E00338 33258 Colorant
D&C red no. 28 E00491 6097185 Colorant
FD&C blue no. 1 E00263 19700 Colorant
FD&C blue no. 2 E00446 2723854 Colorant
Quinoline yellow WS E00309 24671 Colorant
Sodium lauryl sulfate E00464 3423265 Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Stearic acid E00079 5281 Emulsifying agent; Solubilizing agent; Viscosity-controlling agent; lubricant
Sunset yellow FCF E00255 17730 Colorant
Beta-D-lactose E00099 6134 Diluent; Dry powder inhaler carrier; Lyophilization aid
Butyl alcohol E00011 263 Flavoring agent; Solvent
Ferrosoferric oxide E00231 14789 Colorant
Lactose monohydrate E00393 104938 Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate E00208 11177 lubricant
Propylene glycol E00040 1030 Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Talc E00520 16211421 Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
⏷ Show the Full List of 16 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Danazol 200 mg capsule 200 mg Oral Capsule Oral
Danazol 100 mg capsule 100 mg Oral Capsule Oral
Danazol 50 mg capsule 50 mg Oral Capsule Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6942).
2 Danazol FDA Label
3 BDDCS applied to over 900 drugs
4 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
5 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
6 Danazol suppression of luteinizing hormone in the rat: evidence for mediation by both androgen and estrogen receptors. Proc Soc Exp Biol Med. 1990 May;194(1):54-7.
7 A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. Toxicol Sci. 2013 Nov;136(1):216-41.
8 High-content imaging-based BAC-GFP toxicity pathway reporters to assess chemical adversity liabilities. Arch Toxicol. 2017 Mar;91(3):1367-1383. doi: 10.1007/s00204-016-1781-0. Epub 2016 Jun 29.
9 Guillain-Barr syndrome following danazol and corticosteroid therapy for hereditary angioedema. Am J Med. 1985 Jul;79(1):111-4. doi: 10.1016/0002-9343(85)90553-4.
10 Cerner Multum, Inc. "Australian Product Information.".
11 Dutreix C, Munarini F, Lorenzo S, Roesel J, Wang Y "Investigation into CYP3A4-mediated drug-drug interactions on midostaurin in healthy volunteers." Cancer Chemother Pharmacol 72 (2013): 1223-34. [PMID: 24085261]
12 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
13 Product Information. Multaq (dronedarone). sanofi-aventis , Bridgewater, NJ.
14 Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
15 Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
16 Product Information. Ixempra (ixabepilone). Bristol-Myers Squibb, Princeton, NJ.
17 Product Information. Opsumit (macitentan). Actelion Pharmaceuticals US Inc, South San Francisco, CA.
18 Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
19 Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
20 Product Information. Kalydeco (ivacaftor). Vertex Pharmaceuticals, Cambridge, MA.
21 Product Information. Viibryd (vilazodone). Trovis Pharmaceuticals LLC, New Haven, CT.
22 Product Information. Polivy (polatuzumab vedotin). Genentech, South San Francisco, CA.
23 Product Information. Tazverik (tazemetostat). Epizyme, Inc, Cambridge, MA.
24 Product Information. Myrbetriq (mirabegron). Astellas Pharma US, Inc, Deerfield, IL.
25 Product Information. Adcetris (brentuximab vedotin). Seattle Genetics Inc, Bothell, WA.
26 Product Information. Pifeltro (doravirine). Merck & Company Inc, Whitehouse Station, NJ.
27 Product Information. Tivicay (dolutegravir). ViiV Healthcare, Research Triangle Park, NC.
28 Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
29 Product Information. Selzentry (maraviroc). Pfizer U.S. Pharmaceuticals Group, New York, NY.
30 Product Information. Kynamro (mipomersen). Genzyme Corporation, Cambridge, MA.
31 Canadian Pharmacists Association.
32 Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
33 Product Information. Caplyta (lumateperone). Intra-Cellular Therapies, Inc., New York, NY.
34 Product Information. Xalkori (crizotinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
35 Product Information. Zykadia (ceritinib). Novartis Pharmaceuticals, East Hanover, NJ.
36 Product Information. Zepzelca (lurbinectedin). Jazz Pharmaceuticals, Palo Alto, CA.
37 Product Information. Lorbrena (lorlatinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
38 Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
39 Product Information. Gavreto (pralsetinib). Blueprint Medicines Corporation, Cambridge, MA.
40 Al-Nawakil C, Willems L, Mauprivez C, et.al "Successful treatment of l-asparaginase-induced severe acute hepatotoxicity using mitochondrial cofactors." Leuk Lymphoma 55 (2014): 1670-4. [PMID: 24090500]
41 Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
42 Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
43 Product Information. Calquence (acalabrutinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
44 Product Information. Imbruvica (ibrutinib). Pharmacyclics Inc, Sunnyvale, CA.
45 Product Information. Koselugo (selumetinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
46 Product Information. Ubrelvy (ubrogepant). Allergan Inc, Irvine, CA.
47 Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
48 Hamberg P, Woo MM, Chen LC, et al. "Effect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat (LBH589), an orally active histone deacetylase inhibitor." Cancer Chemother Pharmacol 68 (2011): 805-13. [PMID: 21706316]
49 Product Information. Tasigna (nilotinib). Novartis Pharmaceuticals, East Hanover, NJ.
50 Product Information. Rozlytrek (entrectinib). Genentech, South San Francisco, CA.
51 Product Information. Lynparza (olaparib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
52 Product Information. Nuplazid (pimavanserin). Accelis Pharma, East Windsor, NJ.
53 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
54 Product Information. Zokinvy (lonafarnib). Eiger BioPharmaceuticals, Palo Alto, CA.
55 Product Information. Xtandi (enzalutamide). Astellas Pharma US, Inc, Deerfield, IL.
56 Product Information. Rapaflo (silodosin). Watson Pharmaceuticals, Corona, CA.
57 Product Information. Afinitor (everolimus). Novartis Pharmaceuticals, East Hanover, NJ.
58 Product Information. Torisel (temsirolimus). Wyeth-Ayerst Laboratories, Philadelphia, PA.
59 Product Information. Odomzo (sonidegib). Novartis Pharmaceuticals, East Hanover, NJ.
60 Product Information. Orilissa (elagolix). AbbVie US LLC, North Chicago, IL.